BR112015020453A8 - "formas de dosagem de liberação prolongada orais de tofacitinibe e uso de tofacitinibe - Google Patents

"formas de dosagem de liberação prolongada orais de tofacitinibe e uso de tofacitinibe Download PDF

Info

Publication number
BR112015020453A8
BR112015020453A8 BR112015020453A BR112015020453A BR112015020453A8 BR 112015020453 A8 BR112015020453 A8 BR 112015020453A8 BR 112015020453 A BR112015020453 A BR 112015020453A BR 112015020453 A BR112015020453 A BR 112015020453A BR 112015020453 A8 BR112015020453 A8 BR 112015020453A8
Authority
BR
Brazil
Prior art keywords
tofacitinib
dosage forms
release dosage
oral extended
oral
Prior art date
Application number
BR112015020453A
Other languages
English (en)
Other versions
BR112015020453B1 (pt
BR112015020453A2 (pt
Inventor
Kushner Joseph Iv
Lamba Manisha
Max Herbig Scott
Krishnaswami Sriram
C Stock Thomas
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50819757&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112015020453(A8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of BR112015020453A2 publication Critical patent/BR112015020453A2/pt
Publication of BR112015020453A8 publication Critical patent/BR112015020453A8/pt
Publication of BR112015020453B1 publication Critical patent/BR112015020453B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)

Abstract

resumo patente de invenção: "formas de dosagem de liberação prolongada orais de tofacitinibe". a presente invenção refere-se às formulações de liberação prolongada orais de tofacitinibe e sais aceitáveis farmacêuticos das mesmas. as formulações descritas aqui têm características farmacocinéticas desejáveis.
BR112015020453-8A 2013-03-16 2014-03-12 Formas de dosagem de liberação prolongada orais de tofacitinibe e uso de tofacitinibe BR112015020453B1 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201361802479P 2013-03-16 2013-03-16
US61/802,479 2013-03-16
US201361864059P 2013-08-09 2013-08-09
US61/864,059 2013-08-09
US201461934428P 2014-01-31 2014-01-31
US61/934,428 2014-01-31
PCT/IB2014/059689 WO2014147526A1 (en) 2013-03-16 2014-03-12 Tofacitinib oral sustained release dosage forms

Publications (3)

Publication Number Publication Date
BR112015020453A2 BR112015020453A2 (pt) 2017-07-18
BR112015020453A8 true BR112015020453A8 (pt) 2019-11-12
BR112015020453B1 BR112015020453B1 (pt) 2023-03-21

Family

ID=50819757

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015020453-8A BR112015020453B1 (pt) 2013-03-16 2014-03-12 Formas de dosagem de liberação prolongada orais de tofacitinibe e uso de tofacitinibe

Country Status (23)

Country Link
US (4) US9937181B2 (pt)
EP (3) EP2968155B1 (pt)
JP (3) JP6041823B2 (pt)
KR (5) KR20150131238A (pt)
CN (2) CN111419817A (pt)
AU (2) AU2014233850B2 (pt)
BR (1) BR112015020453B1 (pt)
CA (2) CA2905604C (pt)
CY (1) CY1124007T1 (pt)
DK (1) DK2968155T3 (pt)
ES (1) ES2865134T3 (pt)
HK (1) HK1217297A1 (pt)
HU (1) HUE053911T2 (pt)
IL (3) IL241400B (pt)
MX (1) MX2021000550A (pt)
NZ (2) NZ710792A (pt)
PL (1) PL2968155T3 (pt)
PT (1) PT2968155T (pt)
SG (2) SG10201810985XA (pt)
SI (1) SI2968155T1 (pt)
TW (1) TWI619516B (pt)
WO (1) WO2014147526A1 (pt)
ZA (2) ZA201505468B (pt)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6041823B2 (ja) 2013-03-16 2016-12-14 ファイザー・インク トファシチニブの経口持続放出剤形
GB201402070D0 (en) * 2014-02-07 2014-03-26 Galapagos Nv Pharmaceutical compositions for the treatment of inflammatory disorders
US20170151244A1 (en) * 2014-06-23 2017-06-01 Sun Pharmaceutical Industries Limited Oral pharmaceutical composition of tofacitinib
TW201618783A (zh) 2014-08-07 2016-06-01 艾森塔製藥公司 以布魯頓(Bruton)氏酪胺酸激酶(BTK)佔據和BTK再合成速率為基礎之治療癌症、免疫和自體免疫疾病及發炎性疾病之方法
CN104622827A (zh) * 2015-03-05 2015-05-20 重庆华邦制药有限公司 托法替布片剂及其制备方法
KR20180014778A (ko) * 2015-06-03 2018-02-09 트리아스텍 인코포레이티드 제형 및 이의 용도
JP6796083B2 (ja) * 2015-06-09 2020-12-02 カプスゲル・ベルギウム・ナムローゼ・フェンノートシャップＣａｐｓｕｇｅｌ Ｂｅｌｇｉｕｍ ＮＶ カプセル中の薬剤の噴霧乾燥ディスパーションからの迅速な溶解を達成するための製剤
WO2017010938A1 (en) * 2015-07-16 2017-01-19 National University Of Singapore Printing drug tablets with fully customizable release profiles for personalized medicine
EP3328360A4 (en) * 2015-07-27 2019-01-02 Unichem Laboratories Limited Tofacitinib orally disintegrating tablets
US20170049774A1 (en) * 2015-08-19 2017-02-23 Sun Pharmaceutical Industries Limited Sustained release oral pharmaceutical compositions of tofacitinib
US20180311247A1 (en) * 2015-10-02 2018-11-01 Gilead Sciences, Inc. Combination therapies for treating cancers
US11773106B2 (en) 2015-10-16 2023-10-03 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11524964B2 (en) 2015-10-16 2022-12-13 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11512092B2 (en) 2015-10-16 2022-11-29 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US10550126B2 (en) 2015-10-16 2020-02-04 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
EP3362455A1 (en) 2015-10-16 2018-08-22 AbbVie Inc. PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
US11365198B2 (en) 2015-10-16 2022-06-21 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
MX2018012913A (es) 2016-04-22 2019-01-30 Receptor Life Sciences Inc Compuestos medicinales y suplementos nutricionales de base vegetal de rapida accion.
CN108066319B (zh) * 2016-11-10 2022-01-14 江苏先声药业有限公司 一种枸橼酸托法替布肠溶缓释微丸及其制备方法
CN106420648A (zh) * 2016-11-22 2017-02-22 山东淄博新达制药有限公司 枸橼酸托法替布片剂及其制备方法
EA201892396A1 (ru) 2016-12-02 2019-04-30 Ресептор Лайф Сайенсиз, Инк. Быстродействующие растительные лекарственные соединения и биологически активные добавки
KR20180066296A (ko) * 2016-12-07 2018-06-19 서울대학교산학협력단 토파시티닙을 포함하는 고염증 증상의 예방 또는 치료용 약학적 조성물 및 토파시티닙을 포함하는 고염증 증상의 예방 또는 개선용 건강기능식품 조성물
WO2018165250A1 (en) * 2017-03-08 2018-09-13 Theravance Biopharma R&D Ip, Llc Glucuronide prodrugs of tofacitinib
EP3592353A1 (en) 2017-03-09 2020-01-15 AbbVie Inc. Methods of treating crohn's disease and ulcerative colitis
US11564922B2 (en) 2017-03-09 2023-01-31 Abbvie Inc. Methods of treating crohn's disease and ulcerative colitis
US10759865B2 (en) 2017-08-22 2020-09-01 Eyal Levit Treatment of diabetes mellitus
KR102078805B1 (ko) * 2017-11-30 2020-02-19 보령제약 주식회사 토파시티닙을 포함하는 약제학적 조성물
WO2019224058A1 (en) 2018-05-24 2019-11-28 Synthon B.V. Controlled release tofacitinib compositions
US20190381046A1 (en) * 2018-06-14 2019-12-19 Andrew HANNA Tofacitinib and baclofen compositions and applications
CN108992454B (zh) * 2018-06-20 2020-06-02 合肥医工医药股份有限公司 一种治疗皮肤炎症性疾病的复方药物组合物
CN110946834B (zh) * 2018-09-27 2023-03-31 四川科伦药物研究院有限公司 枸橼酸托法替布片及其制备工艺
CN111150711B (zh) * 2018-11-07 2023-04-07 上海博志研新药物技术有限公司 托法替布控释片、制备方法及其应用
CN111358795A (zh) * 2018-12-26 2020-07-03 浙江万晟药业有限公司 一种枸橼酸托法替布制剂及其制备方法
KR20200082006A (ko) * 2018-12-28 2020-07-08 주식회사 대웅제약 토파시티닙 또는 그의 약제학적으로 허용되는 염을 함유한 서방성 제제 및 그의 제조방법
US20220249385A1 (en) * 2019-03-27 2022-08-11 Unichem Laboratories Limited Extended release composition of tofacitinib
WO2021038014A1 (en) 2019-08-29 2021-03-04 Synthon B.V. Controlled release tofacitinib compositions
KR20220101150A (ko) * 2019-11-14 2022-07-19 화이자 인코포레이티드 1-(((2s,3s,4s)-3-에틸-4-플루오로-5-옥소피롤리딘-2-일)메톡시)-7-메톡시이소퀴놀린-6-카복사마이드 조합물 및 경구 투여 형태
CN110787145B (zh) * 2019-12-17 2022-03-29 南京康川济医药科技有限公司 一种枸橼酸托法替布缓释片及其制备方法
CN113018273A (zh) 2019-12-25 2021-06-25 上海宣泰医药科技股份有限公司 一种固体制剂及其制备方法和用途
WO2021169724A1 (zh) * 2020-02-26 2021-09-02 上海博志研新药物技术有限公司 托法替尼缓释剂型、其制备方法及应用
JP7442347B2 (ja) * 2020-03-06 2024-03-04 東京エレクトロン株式会社 基板処理装置及び基板処理方法
US11766438B2 (en) 2020-04-24 2023-09-26 Slayback Pharma Llc Pharmaceutical compositions of tofacitinib for oral administration
BR112022022284A2 (pt) * 2020-05-18 2022-12-20 Zim Laboratories Ltd Nova composição de liberação prolongada de tofacitinibe, seus derivados e sais
CN113712932A (zh) * 2020-05-25 2021-11-30 南京帝昌医药科技有限公司 一种枸橼酸托法替布渗透泵片及其制备方法
US20230270666A1 (en) 2020-07-28 2023-08-31 Fang Zhou Novel gastroretentive extended release dosage form
CN111728953B (zh) * 2020-07-29 2023-08-08 中国科学院上海药物研究所 一种托法替布或其盐的缓释制剂及其制备方法
CN114099499A (zh) * 2020-08-26 2022-03-01 上海博志研新药物技术有限公司 依达拉奉口服持续释放组合物、制备方法及应用
CN112755000A (zh) * 2021-01-21 2021-05-07 石药集团欧意药业有限公司 一种枸橼酸托法替布缓释片
CN113069434A (zh) * 2021-03-11 2021-07-06 绍兴文理学院元培学院 一种枸橼酸托法替布控释胶囊及其制备方法
WO2022254017A1 (en) 2021-06-04 2022-12-08 Synthon B.V. Prolonged release tofacitinib compositions
KR20230071713A (ko) * 2021-11-16 2023-05-23 오즈온바이오 주식회사 산 민감성 무기성분을 포함하는 삼투성 제제 조성물
US20230240998A1 (en) * 2021-12-22 2023-08-03 Hikma Pharmaceuticals Usa Inc. Tofacitinib extended release formulations
WO2024042218A1 (en) 2022-08-26 2024-02-29 Synthon B.V. Prolonged release tofacitinib compositions without functional coating

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2322793A (en) 1939-08-21 1943-06-29 Robert S Drummond Gear finishing tool
US3247066A (en) 1962-09-12 1966-04-19 Parke Davis & Co Controlled release dosage form containing water-swellable beadlet
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3952741A (en) 1975-01-09 1976-04-27 Bend Research Inc. Controlled release delivery system by an osmotic bursting mechanism
US4519801A (en) 1982-07-12 1985-05-28 Alza Corporation Osmotic device with wall comprising cellulose ether and permeability enhancer
US5612059A (en) 1988-08-30 1997-03-18 Pfizer Inc. Use of asymmetric membranes in delivery devices
IL91398A (en) 1988-08-30 1994-05-30 Pfizer A device for the controlled release of pneumatic substances, including the active substance, surrounded by an asymmetric membrane
US5358502A (en) 1993-02-25 1994-10-25 Pfizer Inc PH-triggered osmotic bursting delivery devices
PT621032E (pt) * 1993-04-23 2001-01-31 Novartis Ag Dispositivo de distribuicao de libertacao controlada de farmaco
WO1995030422A1 (en) * 1994-05-06 1995-11-16 Pfizer Inc. Controlled-release dosage forms of azithromycin
US5945125A (en) * 1995-02-28 1999-08-31 Temple University Controlled release tablet
US5736159A (en) 1995-04-28 1998-04-07 Andrx Pharmaceuticals, Inc. Controlled release formulation for water insoluble drugs in which a passageway is formed in situ
US5837379A (en) 1997-01-31 1998-11-17 Andrx Pharmaceuticals, Inc. Once daily pharmaceutical tablet having a unitary core
ID23503A (id) 1997-07-01 2000-04-27 Pfizer Garam-garam sertralina dan bentuk-bentuk sediaan lepas-lambat dari sertralina
FR2766708B1 (fr) 1997-07-30 2000-05-05 Galenix Dev Composition contenant de l'hydroxypropylcellulose, de l'hydroxypropylmethylcellulose et/ou de l'ethylcellullose a titre d'agents desintegrants, et procede d'obtention
US6706283B1 (en) 1999-02-10 2004-03-16 Pfizer Inc Controlled release by extrusion of solid amorphous dispersions of drugs
AU777911B2 (en) * 1999-12-10 2004-11-04 Pfizer Products Inc. Pyrrolo(2,3-d)pyrimidine compounds
IN190699B (pt) 2001-02-02 2003-08-16 Sun Pharmaceutical Ind Ltd
US7301023B2 (en) 2001-05-31 2007-11-27 Pfizer Inc. Chiral salt resolution
KR101016619B1 (ko) * 2001-11-13 2011-02-23 아스텔라스세이야쿠 가부시키가이샤 용해성 약물 지속 방출 시스템
GB0127423D0 (en) 2001-11-15 2002-01-09 Glaxo Group Ltd Process
GT200200234A (es) 2001-12-06 2003-06-27 Compuestos cristalinos novedosos
TW200302748A (en) 2002-02-01 2003-08-16 Pfizer Prod Inc Osmotic delivery system
WO2005020929A2 (en) * 2003-09-02 2005-03-10 Imran Ahmed Sustained release dosage forms of ziprasidone
US7825106B2 (en) 2003-09-03 2010-11-02 Agi Therapeutics Ltd. Modified release formulations and methods of treating inflammatory bowel disease
WO2005053652A1 (en) 2003-12-04 2005-06-16 Pfizer Products Inc. Multiparticulate crystalline drug compositions containing a poloxamer and a glyceride
JP2007513139A (ja) 2003-12-04 2007-05-24 ファイザー・プロダクツ・インク 安定性の改善した多粒子組成物
EP1701702A1 (en) 2003-12-04 2006-09-20 Pfizer Products Inc. Spray-congeal process using an extruder for preparing multiparticulate azithromycin compositions containing preferably a poloxamer and a glyceride
WO2006067576A1 (en) 2004-12-21 2006-06-29 Pfizer Products Inc. Enteric coated azithromycin multiparticulates
ATE413864T1 (de) * 2005-01-27 2008-11-15 Alza Corp Orale osmotische darreichungsform mit membran mit hoher flussdichte
WO2007019393A2 (en) * 2005-08-04 2007-02-15 Alza Corporation Osmotic dosage forms comprising semipermeable membranes with polymer blends providing improved properties
WO2007057762A2 (en) 2005-11-16 2007-05-24 Pfizer Limited Osmotic bi-layer tablet
RU2403016C2 (ru) 2006-04-24 2010-11-10 Пфайзер Продактс Инк. Асимметричные мембраны для устройств доставки лекарственного препарата
CN101460142A (zh) 2006-06-30 2009-06-17 阿肯色大学董事会 缓释有孔片剂
ES2552805T3 (es) 2009-04-20 2015-12-02 Auspex Pharmaceuticals, Llc Inhibidores piperidínicos de la cinasa Janus 3
WO2011039686A1 (en) 2009-09-30 2011-04-07 Pfizer Inc. Latrepirdine oral sustained release dosage forms
US8519970B2 (en) 2010-07-16 2013-08-27 Perceptive Pixel Inc. Capacitive touch sensor having correlation with a receiver
EP2481397A1 (en) * 2011-01-27 2012-08-01 Ratiopharm GmbH Pharmaceutical compositions comprising tasocitinib
EP2481411A1 (en) * 2011-01-27 2012-08-01 Ratiopharm GmbH Oral dosage forms for modified release comprising the JAK3 inhibitor tasocitinib
JP6041823B2 (ja) 2013-03-16 2016-12-14 ファイザー・インク トファシチニブの経口持続放出剤形
WO2014174073A1 (en) 2013-04-26 2014-10-30 Sandoz Ag Sustained release formulations of tofacitinib

Also Published As

Publication number Publication date
US20220142927A1 (en) 2022-05-12
JP2018100300A (ja) 2018-06-28
EP4249055A2 (en) 2023-09-27
KR20210014763A (ko) 2021-02-09
KR20200103892A (ko) 2020-09-02
KR102151842B1 (ko) 2020-09-03
EP2968155A1 (en) 2016-01-20
WO2014147526A1 (en) 2014-09-25
ZA201905100B (en) 2021-07-28
NZ751227A (en) 2020-06-26
RU2018129861A (ru) 2019-03-15
US10639309B2 (en) 2020-05-05
CN111419817A (zh) 2020-07-17
JP2014181234A (ja) 2014-09-29
KR20170121332A (ko) 2017-11-01
IL241400A0 (en) 2015-11-30
CA3037328A1 (en) 2014-09-25
EP2968155B1 (en) 2021-03-03
US20180193347A1 (en) 2018-07-12
EP3854400A1 (en) 2021-07-28
HK1217297A1 (zh) 2017-01-06
HUE053911T2 (hu) 2021-07-28
SG10201810985XA (en) 2019-01-30
JP2016199602A (ja) 2016-12-01
RU2674345C2 (ru) 2018-12-07
EP4249055A3 (en) 2023-12-27
RU2015139505A (ru) 2017-04-24
CN105101952B (zh) 2022-06-28
US20200206232A1 (en) 2020-07-02
IL267967A (en) 2019-08-29
PL2968155T3 (pl) 2021-10-11
CA2905604A1 (en) 2014-09-25
TW201436823A (zh) 2014-10-01
JP6041823B2 (ja) 2016-12-14
AU2014233850B2 (en) 2017-02-23
KR20150131238A (ko) 2015-11-24
SI2968155T1 (sl) 2021-08-31
CA2905604C (en) 2019-05-07
BR112015020453B1 (pt) 2023-03-21
SG11201506103UA (en) 2015-09-29
CY1124007T1 (el) 2022-05-27
IL241400B (en) 2019-07-31
KR102213616B1 (ko) 2021-02-05
US20140271842A1 (en) 2014-09-18
MX2021000550A (es) 2021-04-19
ZA201505468B (en) 2021-06-30
CA3037328C (en) 2023-01-24
US11253523B2 (en) 2022-02-22
TWI619516B (zh) 2018-04-01
JP6314188B2 (ja) 2018-04-18
DK2968155T3 (da) 2021-04-19
BR112015020453A2 (pt) 2017-07-18
NZ710792A (en) 2019-09-27
US9937181B2 (en) 2018-04-10
ES2865134T3 (es) 2021-10-15
IL283032A (en) 2021-06-30
AU2017203334A1 (en) 2017-06-08
HUE053911T4 (hu) 2021-06-28
AU2014233850A1 (en) 2015-08-20
IL267967B (en) 2021-05-31
CN105101952A (zh) 2015-11-25
KR20220151016A (ko) 2022-11-11
PT2968155T (pt) 2021-04-22

Similar Documents

Publication Publication Date Title
BR112015020453A8 (pt) "formas de dosagem de liberação prolongada orais de tofacitinibe e uso de tofacitinibe
CY1125100T1 (el) Υδατικο φαρμακευτικο σκευασμα ταπενταδολης για απο του στοματος χορηγηση
CY1122853T1 (el) Σταθερα σκευασματα λινακλοτιδης
CY1120832T1 (el) Τροποποιητες πυρηνικης μεταφορας και χρησεις αυτων
CY1123953T1 (el) Καθυστερημενης απελευθερωσης συνθεσεις λινακλοτιδης
CY1118379T1 (el) Αναστολεις ιου ηπατιτιδας c
SV2015005115A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
BR112015010663A8 (pt) formas de dosagem oral de liberação sustentada, e uso de ruxolitinib ou de sal farmaceuticamente aceitável do mesmo
BR112015026325A2 (pt) dosagem oral de compostos glp-1
CY1119007T1 (el) Συνθεσεις και μεθοδοι αγωγης πνευμονικης υπερτασης
BR112015020389A2 (pt) compostos carbazol úteis como inibidores de bromodomínio
EA201591363A1 (ru) Аналоги тиадиазола и способы лечения состояний, связанных с дефицитом smn
MX2015008627A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MX369818B (es) Compuestos selectivos de peptido yy (pyy) y usos de los mismos.
CL2012001836A1 (es) Compuestos de pirazol, antagonista de crth2; composicion farmacéutica; uso en el tratamiento de trastornos inflamatorios, infecciosos, inmunoreguladores, enfermedades respiratorias, gastrointestinales o dolencias, entre otros.
EA201491479A1 (ru) Производные лупановых тритерпеноидов и их фармацевтическое применение
BR112014000195A2 (pt) formulações de darunavir
MA41159A (fr) Octréotide destiné à être administré par voie orale en association avec d'autres agents thérapeutiques
BR112014000290A2 (pt) formulações de combinação de darunavir
MX347105B (es) Composiciones farmaceuticas que comprenden hidromorfona y naloxona.
CL2017000329A1 (es) Mejorar el rendimiento miocárdico en pacientes con cirugía de fontan que utilizan composiciones de udenafilo
UY35209A (es) Compuestos tricíclicos
CO6592109A2 (es) Nueva forma cristalina de un derivado de ciclopropilbenzamida
MX2015018040A (es) Agentes terapeuticos para uso en la profilaxis y/o tratamiento de trastornos de movimiento hipercinetico.
IN2014DN10134A (pt)

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 12/03/2014, OBSERVADAS AS CONDICOES LEGAIS

B25G Requested change of headquarter approved

Owner name: PFIZER INC. (US)

B17A Notification of administrative nullity (patentee has 60 days time to reply to this notification)

Free format text: REQUERENTE DA NULIDADE: ASSOCIACAO BRAS DAS INDUSTRIAS DE QUIMICA FINA - ABIFINA. - 870230078827 - 5/9/2023